Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Genentech, a developer of medicine, announced September 30 that the U.S. Food and Drug Administration granted accelerated approval of the company’s medicine pertuzumab (Perjeta)—in combination with trastuzumab (Herceptin) and docetaxel—as pre-surgery treatment for those with high-risk, HER2-positive, inflammatory, early-stage or locally advanced breast cancer.
A study of women with estrogen receptor-positive, invasive breast cancer showed that while most women start and complete treatment with hormonal therapy as prescribed, certain groups are more likely than others to stop taking it before the recommended date, or to never take it at all.
Postmenopausal women with metastatic, hormone receptor-positive breast cancer who are treated with everolimus (Afinitor) plus exemestane (Aromasin) experience delays in cancer progression while maintaining the same quality of life they would have if treated with exemestane alone, a secondary analysis of the BOLERO-2 trial found.
Mindfulness practice has a moderate to large positive impact on improving the mental health of women affected by breast cancer, a recent analysis of nine studies suggests.
NEW YORK (Reuters Health) - Young women with breast cancer often overestimate both their chance of developing cancer in the other breast and how much removal of that breast is likely to protect them, a new U.S. study suggests.
Women age 40 or younger when diagnosed with early-stage, HER2-positive breast cancer do not have an increased risk of early recurrence due to age. They also are as likely as older women to benefit from treatment with trastuzumab, or Herceptin, according to a recent study.
NEW YORK (Reuters Health) - Although recommendations differ on when women should start getting screened for breast cancer, a new study suggests women in their 40s may benefit from yearly mammograms.
NEW YORK (Reuters Health) - How doctors describe a non-invasive type of breast lesion may affect how women choose to have the abnormal cells treated, a new survey suggests.
An analysis of data from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial showed that the older a woman is at diagnosis of hormone-sensitive breast cancer, the greater her chance of distant recurrence over time. Distant recurrence refers to cancer that has spread to a part of the body beyond the breast and regional lymph nodes.
The National Comprehensive Cancer Network (NCCN) issued new guidelines that help doctors focus on the post-treatment needs of individuals diagnosed with and treated for cancer.